Press releases

9th October 2024

STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium

STC-15 is the first METTL3 inhibitor to enter clinical development

Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients

17th June 2024

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery

Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases

3rd June 2024

STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients. Primary objectives were achieved to progress STC-15 into combination with checkpoint inhibitor combination studies.

24th May 2024

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development. Clinical data will include safety, pharmacology, target modulation, and clinical activity.

26th March 2024

STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024

Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024